PCN67 - BUDGET IMPACT MODEL OF SUBCUTANEOUS RITUXIMAB COMPARED WITH INTRAVENOUS RITUXIMAB ON THE TREATMENT OF CD-20 POSITIVE NON-HODGKIN LYMPHOMA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.149
https://www.valueinhealthjournal.com/article/S1098-3015(18)33449-1/fulltext
Section Title :
Section Order :
872
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33449-1&doi=10.1016/j.jval.2018.09.149